Non-Hodgkin’s Lymphoma of the Breast: An Unusual Case Report
Article Sidebar
Main Article Content
Abstract
Primary breast lymphoma is a rare condition accounting for less than 0.5% of all breast malignancies. It typically presents as a solitary mass in women aged 50–60, with clinical and imaging features mimicking breast carcinoma. We present the case of a 60-year-old woman with a right breast nodule diagnosed as marginal zone lymphoma (MZL) by histology. The patient was treated with R-CHOP immunochemotherapy followed by radiotherapy, achieving complete remission with 24 months of sustained follow-up. This case highlights the importance of early histological diagnosis, the occasional diagnostic role of surgery, and the controversies surrounding treatment strategies for breast MZL.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their articles and grant the journal the right of first publication under the Creative Commons Attribution (CC BY) license, which allows others to share and adapt the work with proper attribution.
References
Liu Y, Wang J, Li X, et al. Primary breast marginal zone lymphoma: population-based analysis of incidence, treatment, and survival outcomes. Front Oncol. 2020;10:609512. doi:10.3389/fonc.2020.609512.
Deantonio L, Mazzola R, Trovò M, et al. Radiation therapy of extranodal marginal zone lymphomas. Ann Lymphoma. 2020;4:11. doi:10.21037/aol-20-37.
James S, Patel R, Thompson J, et al. Primary breast marginal zone lymphoma: a rare indolent entity with diagnostic and therapeutic challenges. JPRAS Open. 2022;33:16–20. doi:10.1016/j.jpra.2022.02.007.
Walewska R, Smith A, Brown K, et al. British Society for Haematology guidelines for the diagnosis and management of marginal zone lymphomas. Br J Haematol. 2024;205(1):45–63. doi:10.1111/bjh.19064.
National Cancer Institute. PDQ® Adult Treatment Editorial Board. Indolent B-cell non-Hodgkin lymphoma treatment (PDQ®): health professional version. Updated 2025. Available from: https://www.cancer.gov/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq.